argenx NV ADR (ARGX)vsCue Biopharma (CUE)
ARGX
argenx NV ADR
$984.39
+0.04%
HEALTHCARE · Cap: $64.63B
CUE
Cue Biopharma
$28.74
+2.64%
HEALTHCARE · Cap: $208.78M
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 14016% more annual revenue ($5.32B vs $37.66M). ARGX leads profitability with a 32.3% profit margin vs 0.0%. ARGX earns a higher WallStSmart Score of 73/100 (B).
ARGX
Strong Buy73
out of 100
Grade: B
CUE
Avoid27
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+64.8%
Fair Value
$2371.09
Current Price
$984.39
$1386.70 discount
Intrinsic value data unavailable for CUE.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 31 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 32.0%
Revenue surging 59.3% year-over-year
Earnings expanding 95.2% YoY
Conservative balance sheet, low leverage
Revenue surging 166.7% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Trading at 183.0x book value
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Trading at 65.3x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 32.3% and operating margin at 32.0%. Revenue growth of 59.3% demonstrates continued momentum.
Bull Case : CUE
The strongest argument for CUE centers on Revenue Growth. Revenue growth of 166.7% demonstrates continued momentum.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, Price/Book.
Bear Case : CUE
The primary concerns for CUE are EPS Growth, Market Cap, Profit Margin. Debt-to-equity of 3.81 is elevated, increasing financial risk.
Key Dynamics to Monitor
ARGX profiles as a growth stock while CUE is a hypergrowth play — different risk/reward profiles.
CUE carries more volatility with a beta of 2.46 — expect wider price swings.
CUE is growing revenue faster at 166.7% — sustainability is the question.
ARGX generates stronger free cash flow (749M), providing more financial flexibility.
Bottom Line
ARGX scores higher overall (73/100 vs 27/100), backed by strong 32.3% margins and 59.3% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Cue Biopharma
HEALTHCARE · BIOTECHNOLOGY · USA
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biological drugs for the selective modulation of the human immune system to treat a variety of cancers, chronic infectious diseases, and autoimmune disorders. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?